Given the science on malnutrition, how does the clinician respond? Practical lessons for and application to the dialysis patient

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue SUPPL. 1, 2009, Pages

  Lecker, Stewart H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ATROGIN 1; BORTEZOMIB; CASPASE 3; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEGESTROL ACETATE; MUSCLE RING FINGER 1 PROTEIN; MYOSIN; NANDROLONE DECANOATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3;

ADRENAL INSUFFICIENCY; CACHEXIA; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; EXERCISE; HEALTH CARE COST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOGONADISM; INFLAMMATION; INSULIN RESISTANCE; INTRADIALYTIC PARENTERAL NUTRITION; KIDNEY FAILURE; MALNUTRITION; METABOLIC ACIDOSIS; MUSCLE ATROPHY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; SIGNAL TRANSDUCTION; THERAPY EFFECT; THROMBOEMBOLISM; UREMIA; VIRILIZATION;

CACHEXIA; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCLE PROTEINS; MUSCULAR ATROPHY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 73849152843     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02650409     Document Type: Conference Paper

References (72)

1. Lim VS, Kopple JD: Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int 58: 1-10, 2000
2. Bailey JL, Wang X, England BK, Price SR, Ding X, Mitch WE: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97: 1447-1453, 1996
3. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905, 1996
4. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS, Mitch WE: Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98: 1703-1708, 1996
5. DeFronzo RA, Smith D, Alvestrand A: Insulin action in uremia. Kidney Int Suppl 16: S102-S114, 1983
6. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
7. Hasselgren PO: Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 2: 201-205, 1999
8. Du J, Mitch WE, Wang X, Price SR: Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J Biol Chem 275: 19661-19666, 2000
9. Price SR, England BK, Bailey JL, Van Vreede K, Mitch WE: Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. Am J Physiol 267: C955-C960, 1994
10. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 21: 1857-1869, 2007
11. Movilli E, Zani R, Carli O, Sangalli L, Pola A, Camerini C, Cancarini GC, Scolari F, Feller P, Maiorca R: Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: A prospective study. Nephrol Dial Transplant 13: 1719-1722, 1998
12. Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R: Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95: 39-45, 1995
13. May RC, Kelly RA, Mitch WE: Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: Influence of metabolic acidosis. J Clin Invest 79: 1099-1103, 1987
14. Gutierrez A, Alvestrand A, Wahren J, Bergstrom J: Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 38: 487-494, 1990
15. Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, Flakoll PJ: Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 282: E107-E116, 2002
16. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004
17. Williams A, Sun X, Fischer JE, Hasselgren PO: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 126: 744-749, 1999
18. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren PO: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 99: 163-168, 1997
19. Mansoor O, Beaufrere B, Boirie Y, Ralliere C, Taillandier D, Aurousseau E, Schoeffler P, Arnal M, Attaix D: Increased mRNA levels for components of the lysosomal, Ca2+-activated, and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proc Natl Acad Sci U S A 93: 2714-2718, 1996
20. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J: Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61: 1286-1292, 2002
21. Pickart CM: Back to the future with ubiquitin. Cell 116: 181-190, 2004
22. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82: 373-428, 2002
23. Baumeister W, Walz J, Zuhl F, Seemuller E: The proteasome: Paradigm of a self-compartmentalizing protease. Cell 92: 367-380, 1998
24. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001
25. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98: 14440-14445, 2001
26. Solomon V, Goldberg AL: Importance of the ATP-ubiquitin-proteasome pathway n the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271: 26690-26697, 1996
27. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998
28. DeFronzo RA, Beckles AD: Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236: E328-E334, 1979
29. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesityinduced insulin resistance. Science 271: 665-668, 1996
30. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE: Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113: 115-123, 2004
31. Workeneh B, Balakumaran A, Bichet DG, Mitch WE: The dilemma of diagnosing the cause of hypernatraemia: Drinking habits vs diabetes insipidus. Nephrol Dial Transplant 19: 3165-3167, 2004
32. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019, 2001
33. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE: Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15: 1537-1545, 2004
34. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE: Chronic kidney disease causes defects in signaling through the insulin receptor substrate/ phosphatidylinositol 3-kinase/Akt pathway: Implications for muscle atrophy. J Am Soc Nephrol 17: 1388-1394, 2006
35. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004
36. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004
37. Hunter RB, Kandarian SC: Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114: 1504-1511, 2004
38. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298, 2004
39. Lacson E Jr, Ikizler TA, Lazarus JM, Teng M, Hakim RM: Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 17: 363-371, 2007
40. Leon JB, Majerle AD, Soinski JA, Kushner I, Ohri-Vachaspati P, Sehgal AR: Can a nutrition intervention improve albumin levels among hemodialysis patients? A pilot study. J Ren Nutr 11: 9-15, 2001
41. Akpele L, Bailey JL: Nutrition counseling impacts serum albumin levels. J Ren Nutr 14: 143-148, 2004
42. Caglar K, Fedje L, Dimmitt R, Hakim RM, Shyr Y, Ikizler TA: Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 62: 1054-1059, 2002
43. Fouque D, McKenzie J, de Mutsert R, Azar R, Teta D, Plauth M, Cano N: Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 23: 2902-2910, 2008
44. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de Mutsert R, Engfer M, Elia M: Multinutrient oral supplements and tube feeding in maintenance dialysis: A systematic review and meta-analysis. Am J Kidney Dis 46: 387-405, 2005
45. Mortelmans AK, Duym P, Vandenbroucke J, De Smet R, Dhondt A, Lesaffer G, Verwimp H, Vanholder R: Intradialytic parenteral nutrition in malnourished hemodialysis patients: A prospective long-term study. J Parenter Enteral Nutr 23: 90-95, 1999
46. Chertow GM, Ling J, Lew NL, Lazarus JM, Lowrie EG: The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients. Am J Kidney Dis 24: 912-920, 1994
47. Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA: Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 17: 3149-3157, 2006
48. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA: Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest 110: 483-492, 2002
49. Cano NJ, Fouque D, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Laville M, Leverve XM: Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 18: 2583-2591, 2007
50. Ikizler TA: Nutrition support for the chronically wasted or acutely catabolic chronic kidney disease patient. Semin Nephrol 29: 75-84, 2009
51. Johansen KL: Exercise and chronic kidney disease: Current recommendations. Sports Med 35: 485-499, 2005
52. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45[Suppl 3]: S1-S153, 2005
53. Kopple JD, Wang H, Casaburi R, Fournier M, Lewis MI, Taylor W, Storer TW: Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 18: 2975-2986, 2007
54. Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR: Mixed muscle protein synthesis and breakdown after resistance exercise in humans. Am J Physiol 273: E99-E107, 1997
55. Louis E, Raue U, Yang Y, Jemiolo B, Trappe S: Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol 103: 1744-1751, 2007
56. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 17: 2307-2314, 2006
57. Cheema B, Abas H, Smith B, O'Sullivan A, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, Fiatarone Singh M: Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: The Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kidney Dis 50: 574-584, 2007
58. Goldstein SL, Montgomery LR: A pilot study of twice-weekly exercise during hemodialysis in children. Pediatr Nephrol 24: 833-839, 2009
59. Bossola M, Muscaritoli M, Tazza L, Giungi S, Tortorelli A, Rossi Fanelli F, Luciani G: Malnutrition in hemodialysis patients: What therapy? Am J Kidney Dis 46: 371-386, 2005
60. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C: Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 15: 345-355, 2005
61. Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM: High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 29: 136-140, 2006
62. Bodenner DL, Medhi M, Evans WJ, Sullivan DH, Liu H, Lambert CP: Effects of megestrol acetate on pituitary function and end-organ hormone secretion: A post hoc analysis of serum samples from a 12-week study in healthy older men. Am J Geriatr Pharmacother 3: 160-167, 2005
63. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 281: 1275-1281, 1999
64. Feldt-Rasmussen B, El Nahas M: Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Semin Nephrol 29: 50-58, 2009
65. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wan-ner C, Wiedemann J, Ikizler TA: OPPORTUNITY: A randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 3: 1741-1751, 2008
66. Spanner E, Suri R, Heidenheim AP, Lindsay RM: The impact of quotidian hemodialysis on nutrition. Am J Kidney Dis 42[Suppl]: 30-35, 2003
67. Galland R, Traeger J: Short daily hemodialysis and nutritional status in patients with chronic renal failure. Semin Dial 17: 104-108, 2004
68. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D: Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int 60: 1555-1560, 2001
69. Galland R, Traeger J, Arkouche W, Delawari E, Fouque D: Short daily hemodialysis and nutritional status. Am J Kidney Dis 37[Suppl 2]: S95-S98, 2001
70. Painter P, Johansen KL: Improving physical functioning: Time to be a part of routine care. Am J Kidney Dis 48: 167-170, 2006
71. Bhasin S, Jasuja R: Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12: 232-240, 2009
72. Biolo G, Ciocchi B, Bosutti A, Situlin R, Toigo G, Guarnieri G: Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis 40: 1162-1172, 2002